ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. CDC. Antibiotic resistance threats in the United States, 2013. Available at: www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed Oct 7, 2014.
-
2. File TM Jr, Srinivasan A, Bartlett JG. Antimicrobial stewardship: importance for patient and public health. Clin Infect Dis 2014; 59 (suppl 3): S93–S96.
-
3. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159–177.
-
4. President's Council of Advisors on Science and Technology. Report to the President on combatting antibiotic resistance. Available at: www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf. Accessed Nov 21, 2014.
-
5. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012; 33: 322–327.
-
6. Dortch MJ, Fleming SB, Kauffmann RM, et al. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt) 2011; 12: 15–25.
-
7. Fishman N. Antimicrobial stewardship. Am J Infect Control 2006; 34 (suppl 1): S55–S63.
-
8. Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from a community hospital's antimicrobial stewardship program. Am J Infect Control 2013; 41: 145–148.
-
9. Schultz L, Lowe TJ, Srinivasan A, et al. Economic impact of redundant antimicrobial therapy in US hospitals. Infect Control Hosp Epidemiol 2014; 35: 1229–1235.
-
10. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505–511.
-
11. US FDA Center for Veterinary Medicine. The judicious use of medically important antimicrobial drugs in food producing animals (guidance for industry No. 209). Available at: www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624.pdf. Accessed Oct 1, 2014.
-
12. US FDA Center for Veterinary Medicine. New animal drugs and new animal drug combination products administered in or on medicated feed or drinking water of food-producing animals: recommendations for drug sponsors for voluntary aligned product use conditions with GFI #209 (guidance for industry No. 213). Available at: www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM299624.pdf. Accessed Oct 1, 2014.
-
13. Hillier A, Lloyd DH, Weese JS, et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol 2014; 25: 163–175.
-
14. Weese JS, Blondeau JM, Boothe D, et al. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases. Vet Med Int 2011; 2011: 263768.
Advertisement
Antimicrobial stewardship in companion animal practice
Contributor Notes
Members of the Task Force for Antimicrobial Stewardship in Companion Animal Practice: Jeff B. Bender, DVM, MS, (Chair), Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN 55108; Tamar F. Barlam, MD, MSc, Infectious Disease Section, Boston Medical Center, 1 Boston Medical Center Place, Boston, MA 02118 (representing the Infectious Disease Society of America); Reilly P. Glore, DVM, Brady Veterinary Hospital, 450 Monte Brady Rd, Montesano, WA 98563 (representing the American Animal Hospital Association); Nigel Gumley, DVM, Canadian Veterinary Medical Association, 339 Booth St, Ottawa, ON K1R 7K1, Canada; Sharon E. Grayzel, DVM, MPH, Columbia Veterinary Center, 5106 NE 78th St, Vancouver, WA 98665; Christine Hoang, DVM, MPH, AVMA, 1931 N Meacham Rd, Schaumburg, IL 60173; Michael J. Murphy, DVM, PhD, Center for Veterinary Medicine, US FDA, 7519 Standish Place, Rockville, MD 20855; Mark G. Papich, DVM, MS, Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27607; Jane E. Sykes, BVSc, PhD, Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616; Jeffrey L. Watts, PhD, Anti-Infectives Research VMRD, Zoetis, 333 Portage St, Kalamazoo, MI 49009 (representing the Animal Health Institute); Jean M. Whichard, CDC, Mailstop G29, 1600 Clifton Rd, Atlanta, GA 30329.
Powered by PubFactory